1-7 of 7
Andrew Rawstron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Talha Munir, Abraham Mullasseril Varghese, Adrian Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankara Paneesha, Christopher P Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, Prof. John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Anna Hockaday, David A. Cairns, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, David Stones, Nichola McWhirter, Surita Dalal, Andrew Rawstron, Piers Patten, Peter Hillmen
Journal: Blood
Blood (2024) 144 (Supplement 1): 585.
https://doi.org/10.1182/blood-2024-211449
Published: 2024
Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

David John Lewis, Mats Jerkeman, Lexy Sorrell, David Wright, Ingrid Glimelius, Annika Pasanen, Jacob Haaber Christensen, Karin Fahl Wader, Andrew J. Davies, Nick Morley, Christopher McNamara, Christian Bjørn Poulsen, Jon Riise, Kristina Sonnevi, Ingemar Lagerlöf, Cathy Burton, Surita Dalal, Andrew Rawstron, Ruth M de Tute, Victoria Allgar, Sree Aroori, Mark Warner, Brian Wainman, Claire Scully, Jeanette Sanders, Carsten Utoft Niemann, Helle Toldbod, Nicola Crosbie, Mark J Bishton, Toby A. Eyre, Simon Rule
Journal: Blood
Blood (2024) 144 (Supplement 1): 235.
https://doi.org/10.1182/blood-2024-199710
Published: 2024
Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Peter Hillmen, David Allan Cairns, Adrian John Clifton Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankaranarayana Paneesha, Christopher P. Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth M de Tute, Andrew Rawstron, Piers EM Patten, Talha Munir
Journal: Blood
Blood (2023) 142 (Supplement 1): 631.
https://doi.org/10.1182/blood-2023-178298
Published: 2023
Journal Articles

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Vanitha Ramakrishnan, Linlin Xu, Jason C. Paik, Carol Marimpietri, Eric Shen, Xiaoxi Dong, Jessica Li, Andreas Agathangelidis, Tian Tian, Aileen Cleary Cohen, Tadeusz Robak, Constantine S. Tam, Paolo Ghia, Andrew Rawstron, Jennifer R. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 1902.
https://doi.org/10.1182/blood-2023-174543
Published: 2023
Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Talha Munir, Alexandra Pitchford, Adrian Bloor, Andrew Pettitt, Piers E.M. Patten, Francesco Forconi, Anna Schuh, Christopher P Fox, Simona Gatto, Ben Kennedy, John Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Nichola McWhirter, Jane Shingles, Kate Cwynarski, Shankara Paneesha, David Allsup, Andrew Rawstron, Peter Hillmen
Journal: Blood
Blood (2022) 140 (Supplement 1): 231–233.
https://doi.org/10.1182/blood-2022-170463
Published: 2022
Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Nichola Webster, Surita Dalal, PhD, Kristian Brock, PhD, Francesca Yates, PhD, Chhaya Sankhalpara, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Christopher Fegan, Alison McCaig, MBChB, FRCPath, PhD MRCP, Anna Schuh, MD MRCP, PhD, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Piers Patten, MD PhD, Stephen Devereux, PhD FRCP, FRCPath, MRCPath, MB BS, Adrian Bloor, PhD FRCP, FRCPath, Christopher P Fox, PhD FRCPath, MRCP, MBChB, Francesco Forconi, MD PhD FRCPath, Andrew Rawstron, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-136960
Published: 2020
Journal Articles

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Andrea GS Pepper, PhD, Antonella Zucchetto, PhD, Kevin Norris, PhD, Erika Tissino, PhD, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, MBChB, PhD, Andrew Rawstron, PhD, Daniel Catovsky, MD FRCP, Riccardo Bomben, PhD, Duncan M Baird, PhD, Christopher Fegan, Valter Gattei, MD, Chris Pepper, BSc, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-141279
Published: 2020